The stock's fall snapped a two-day winning streak.
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie received Food and Drug Administration approval of Emblaveo, an intravenous antibiotic, for treatment of adults with complicated intra-abdominal infections with limited or no treatment options.
This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, AstraZeneca AZN and AbbVie announced their fourth-quarter and full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results